AnaptysBio, Inc. (ANAB) shares rallied 30.5% in the last trading session to close at $16.15. This move can be attributable to notable volume with a higher number of shares being traded than in a ...
ANAB will conduct ongoing workshops and webinars regarding the requirements under ANSI/ASTM E2659-24, and encourages certificate issuers to analyze and familiarize themselves with the requirements ...
Has AnaptysBio, Inc. (ANAB) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
ANAB remains risky despite new clinical data and partnerships; past successes haven't been replicated, and management's transparency issues raise concerns. The recent deal for Imsidolimab reflects ...
ANAB will conduct ongoing workshops and webinars regarding the requirements under ANSI/ASTM E2659-24, and encourages certificate issuers to analyze and familiarize themselves with the requirements of ...
Shares of AnaptysBio (NASDAQ:ANAB) climbed ~12% in the premarket on Wednesday after the biotech said its lead asset, rosnilimab, reached the main goals in a mid-stage trial targeted at the ...
JPMorgan raised the firm’s price target on AnaptysBio (ANAB) to $42 from $36 and keeps an Overweight rating on the shares. The firm updated models in the Smid-cap biotechnology group.
AnaptysBio (NASDAQ:ANAB – Get Free Report) will likely be releasing its earnings data before the market opens on Monday, March 10th. Analysts expect AnaptysBio to post earnings of ($1.55 ...
Guggenheim raised the firm’s price target on AnaptysBio (ANAB) to $52 from $36 and keeps a Buy rating on the shares following the company’s Q4 update. The firm is “encouraged” by the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results